Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
1991-5-31
|
| pubmed:abstractText |
Interleukin 2 (IL-2) at a dose of 10,000 to 20,000 U/kg/q 8 hr was given for 9-12 days to six patients with cases of severe atopic dermatitis (AD) which were refractory to conventional therapy. After IL-2 therapy, the clinical symptoms and signs of eczema including pruritus, scratching, papulovesicles, and lichenification were much improved, but all of them recurred 2-6 weeks after stopping treatment. Adverse reactions were similar to those reported previously, but all of them subsided after discontinuation of therapy. Laboratory findings showed decreased T-cell subsets, especially CD4+ cells, and increased IL-2R+ (CD25) cells, but there was no significant change in serum IL-2, serum IgE, or in vitro IgE production. Immunopathological studies of the skin biopsies showed decreased mononuclear-cell infiltration, depletion of CD4+ cells, and enhanced expression of CD25 and HLA-DR antigens. As lymphokine-activated killer (LAK)-cell activity against cultured fibroblasts was similar in patients with AD and in normals and CD1+ Langerhans cells were not decreased after IL-2 therapy, we speculate that the depletion of helper/inducer CD4+ cells and hence abrogation of the exaggerated antigen processing and cellular activation in diseased skin are the explanation for the transient efficacy of IL-2 in the treatment of atopic dermatitis.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jan
|
| pubmed:issn |
0271-9142
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
11
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
22-8
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:1673687-CD4-Positive T-Lymphocytes,
pubmed-meshheading:1673687-Child,
pubmed-meshheading:1673687-Child, Preschool,
pubmed-meshheading:1673687-Cytotoxicity, Immunologic,
pubmed-meshheading:1673687-Dermatitis, Atopic,
pubmed-meshheading:1673687-Female,
pubmed-meshheading:1673687-Fibroblasts,
pubmed-meshheading:1673687-Humans,
pubmed-meshheading:1673687-Immunoglobulin E,
pubmed-meshheading:1673687-Interleukin-2,
pubmed-meshheading:1673687-Leukocyte Count,
pubmed-meshheading:1673687-Male,
pubmed-meshheading:1673687-Prognosis,
pubmed-meshheading:1673687-Receptors, Interleukin-2,
pubmed-meshheading:1673687-Recombinant Proteins,
pubmed-meshheading:1673687-Recurrence,
pubmed-meshheading:1673687-Skin,
pubmed-meshheading:1673687-T-Lymphocyte Subsets
|
| pubmed:year |
1991
|
| pubmed:articleTitle |
Interleukin 2 therapy in severe atopic dermatitis.
|
| pubmed:affiliation |
Department of Pediatrics, National Taiwan University Hospital, Taipei, Republic of China.
|
| pubmed:publicationType |
Journal Article
|